Full Year 2026 Financial Guidance

For the full year 2026, BrightSpring is increasing Revenue and Adjusted EBITDA guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2025 Revenue and Adjusted EBITDA results, excluding the Community Living business:

  • Revenues of $14,725 million to $15,225 million, or 14.1% to 17.9% growth.
    • Pharmacy Segment Revenue of $12,850 million to $13,300 million, or 12.3% to 16.2% growth.
    • Provider Segment Revenue of $1,875 million to $1,925 million, or 28.0% to 31.4% growth.
  • Total Adjusted EBITDA5 of $795 million to $825 million, or 28.7% to 33.6% growth.
  • The Amedysis and LHC acquisition is expected to contribute approximately $30 million in Adjusted EBITDA in 2026.